Novo Nordisk’s multibillion-dollar honeymoon phase spearheaded by Ozempic and Wegovy is ending. Now the Danish drugmaker is ...

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Eli Lilly's corresponding weight-loss drugs to Novo Nordisk's obesity drug Wegovy and diabetes treatment Ozempic are Zepbound and Mounjaro, positioning the firm as a major rival to the Danish ...

Telehealth company Hims Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead this lucrative and fast-growing market. However, Novo Nordisk (NYSE ...

Recently, Novo Nordisk revealed trial results for two new obesity drugs, CagriSema and Amycretin. The former disappointed investors with less-than-projected weight loss, resulting in ... are now ...